Company / Return on Assets (ROA)
Arbutus Biopharma Corp Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-35.4%
FY2025
5-year range
-53.1% / -35.4%
FY2021-FY2025
Trend
+33.3%
vs FY2024
Sector context
#149 of 213
Health Care
What the data says
At -35.4%, Arbutus Biopharma Corp's return on assets (roa) ranks #149 of 213 in the Health Care sector. Return on Assets (ROA) returned to growth in FY2025 after 2 years of decline, reaching -35.4%.
Based on SEC 10-K filings.
-35.4% in FY2025 with a 5-year CAGR of +76.7%.
Improved from -50.4% to -35.4% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +0.1pp
- 5-Year Change
- +76.7pp
- 10-Year Change
- -
Sector benchmark
#149 of 213 in Health CareTop 70% of 213This company -35.4% Sector average -24.1%
▼
-46.7% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 33.3% year-over-year.
- Currently 11.3pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2019.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -35.4% | +33.3% |
| FY2024 | -53.1% | -5.2% |
| FY2023 | -50.4% | -42.0% |
| FY2022 | -35.5% | +4.7% |
| FY2021 | -37.3% | +66.7% |
| FY2020 | -112.1% | -383.6% |
| FY2019 | -23.2% | +37.4% |
| FY2018 | -37.0% | -4.1% |
| FY2017 | -35.6% | +74.4% |
| FY2016 | -139.2% | -1480.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026